Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Rozanolixizumab in CIDP
2018-004392-12Phase 2Unknown
- Sponsor
- UCB
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rozanolixizumab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by UCB. Primary endpoint: Treatment-emergent adverse events. Status: unknown.
02
Drugs
rozanolixizumab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2018-004392-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004392-12.